Data completeness
0/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEMARIL (trimeprazine tartrate) is an oral syrup formulation of a phenothiazine derivative developed by AbbVie. The mechanism of action and specific indications are not publicly disclosed in available data. This product is in pre-launch stage and represents a legacy small-molecule asset repositioned for modern clinical use.
Pre-Launch
Pre-launch stage indicates early-stage commercial build-out; limited team size but growth opportunity if approval succeeds.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TEMARIL offers early-stage launch exposure within AbbVie's commercial infrastructure. Career growth depends on successful regulatory approval and market adoption of this repositioned asset.
Brand ManagerRegulatory Affairs Specialist
Worked on TEMARIL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.